Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up

AUTHORS

Hassan Taheri 1 , * , Mohammad Reza Hasanjani Roushan 2 , Mohammad JafarSoleimani Amiri 2 , Mohammad Pouralijan 2 , Ali Bijani 2

1 Infectious Diseases Research Center, Babol University of Medical Sciences, [email protected], IR Iran

2 Infectious Diseases Research Center, Babol University of Medical Sciences, IR Iran

How to Cite: Taheri H, Roushan M R, Amiri M, Pouralijan M, Bijani A. Efficacy of Hepatitis B vaccine in those who lost Hepatitis B surface antigen during follow-up, Hepat Mon. Online ahead of Print ; 11(2):119-122.

ARTICLE INFORMATION

Hepatitis Monthly: 11 (2); 119-122
Article Type: Research Article
Received: August 30, 2010
Accepted: December 25, 2010

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: The level of HBsAg in some chronic hepatitis B virus (HBV)-infected individuals may decline over time so that it is not detectable in serum.
Objective: To assess the efficacy of HBV vaccine in those who lost their HBsAg without seroconverssion to anti-HBs antibody.
Patients and Methods: From April 1993 to December 2008, of 1603 chronic HBV-infected individuals, 34 (22 men and 12 women) became HBsAg-negative in follow-up visits, with no detectable anti-HBs antibody and HBV DNA in their sera. They received HBV vaccination at 0, 1 and 6 months (case group). Fifty-two subjects (30 men and 22 women) who were negative for HBsAg, anti-HBs and anti-HBc antibody, received HBV vaccination according to the said schedule (control group). Anti-HBs antibody was assessed one month after the last dose of vaccination in the both groups.
Results: The mean±SD age of the case and control groups was 38±12.7 and 33.4±8.6 years, respectively (p=0.07). The sex distribution between these two groups were similar (p=0.652). The mean±SD years of follow-up for the case group was 7.6±4.5 years. Anti-HBs antibody level ≥10 IU/L was found in 8 (24%) subjects in the case group and in 45 (87%) in the control group (p<0.001). The mean±SD anti-HBs antibody level in the case group was 68±32.66 and in the control group 344.6±38.9 IU/L (p<0.001).
Conclusions: We found that nearly 24% of chronic HBsAg-positive subjects who lost their HBsAg responded to HBV and the remaining cases need to be followed for occult HBV infection.

Keywords

Chronic hepatitis B Follow-up study HBsAg Hepatitis B virus Hepatitis B vaccine

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: